2025 · 3rd Quarter (July 1 - Sep 30)
Filed by ARENTFOX SCHIFF LLP.
Open official filingSource-reported fields
Literal source text
Section 340B Drug Pricing Program Sickle cell disease research funding generally Drug pricing reforms generally Mental and behavioral health legislation generally H.R. 2107 (Children's Hospital GME Support Reauthorization Act of 2025), all provisions Site neutral payments to providers generally Federal telehealth policy generally
Literal federal measure citations: H.R. 2107
Autism research programs and autism intervention programs generally, including Medicaid coverage of detection methodologies Department of Health and Human Services programs regarding autism and sickle cell disease research Fiscal Year 2025 Department of Health and Human Services funding regarding National Institutes of Health funding, Children's Hospital Graduate Medical Education (CHGME) program, sickle cell disease research, and other programs related to pediatric health care H.R. 5304 and S. 2587 (Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026), Title II, regarding National Institutes of Health funding, Children's Hospital Graduate Medical Education (CHGME) program, sickle cell disease research, and other programs related to pediatric health care H.R. 1 (One Big Beautiful Bill Act), Sections 71115, 71116, regarding Medicaid funding
Literal federal measure citations: H.R. 5304, S. 2587, H.R. 1
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.
